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Synthesis of a DNA-targeting nickel (II) complex with testosterone thiosemicarbazone 
which exhibits selective cytotoxicity towards human prostate cancer cells (LNCaP) 
ABSTRACT 
Testosterone thiosemicarbazone, L and its nickel (II) complex 1 were synthesized and 
characterized by using FTIR, CHN, (1)H NMR, and X-ray crystallography. X-ray diffraction 
study confirmed the formation of L from condensation of testosterone and thiosemicarbazide. 
Mononuclear complex 1 is coordinated to two Schiff base ligands via two imine nitrogens 
and two tautomeric thiol sulfurs. The cytotoxicity of both compounds was investigated via 
MTT assay with cisplatin as positive reference standard. L is more potent towards androgen-
dependent LNCaP (prostate) and HCT 116 (colon). On the other hand, complex 1, which is in 
a distorted square planar environment with L acting as a bidentate NS-donor ligand, is 
capable of inhibiting the growth of all the cancer cell lines tested, including PC-3 (prostate). 
It is noteworthy that both compounds are less toxic towards human colon cell CCD-18Co. 
The intrinsic DNA binding constant (Kb) of both compounds were evaluated via UV-Vis 
spectrophotometry. Both compounds showed Kb values which are comparable to the reported 
Kb value of typical classical intercalator such as ethidium bromide. The binding constant of 
the complex is almost double compared with ligand L. Both compounds were unable to 
inhibit the action topoisomerase I, which is the common target in cancer treatment (especially 
colon cancer). This suggest a topoisomerase I independent-cell death mechanism. 
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